Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Glucagon-Like Peptide-1 is a natural hormone that regulates blood sugar, controls appetite, and slows digestion
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
Enabling a new era in minimally invasive obesity treatment across Europe
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Expanding US operations to address the increased demand for API development and manufacturing
Subscribe To Our Newsletter & Stay Updated
